Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
:SUNPHARMA
Want to see IN:SUNPHARMA full AI Analyst Report?
SUNPHARMA Stock Chart & Stats
₹1730.15
-₹15.65(-0.84%)
At close: 4:00 PM EST
₹1730.15
-₹15.65(-0.84%)
Day’s Range― - ―
52-Week Range₹1,547.25 - ₹1,917.15
Previous CloseN/A
Volume1.30M
Average Volume (3M)102.58K
Market Cap
₹4.29T
Enterprise Value₹4.25T
Total Cash (Recent Filing)₹278.80B
Total Debt (Recent Filing)₹52.15B
Price to Earnings (P/E)37.4
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
11.59Next Dividend Ex-DateN/A
Dividend Yield0.91%
Share Statistics
EPS (TTM)43.60
Shares Outstanding2,399,278,300
10 Day Avg. Volume56,056
30 Day Avg. Volume102,581
Financial Highlights & Ratios
PEG Ratio7.62
Price to Book (P/B)5.05
Price to Sales (P/S)7.22
P/FCF Ratio45.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.17
Revenue Forecast (FY)₹650.53B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetSun Pharma's low leverage (debt-to-equity roughly ~3%–12% historically and ~5.5% in the latest year) indicates durable financial flexibility. This conservative capital structure supports funding R&D, m&a, or downturns without forcing dilutive financing, preserving strategic optionality.
Consistent Revenue And Net MarginsA multi-year revenue uptrend with generally strong net margins (~19–21%) reflects a resilient business mix of generics and specialty products. This persistent top-line growth and margin profile underpin sustainable cash generation and support long-term competitiveness across geographies.
Reliable Free Cash Flow GenerationConsistent positive free cash flow, with FCF around 72% of net income recently, provides durable internal funding for capex, working capital and shareholder returns. Strong FCF underpins strategic reinvestment and reduces dependence on external financing over the medium term.
Bears Say
Sharp Gross-margin DeclineA steep gross-margin drop (from ~78% to ~56.7%) signals structural headwinds like pricing pressure, cost inflation, or adverse product-mix shifts. Such a material margin contraction can persistently compress operating leverage and limit room for investment or margin restoration without strategic actions.
Inconsistent Operating Cash ConversionRepeatedly lower operating cash versus net income and coverage between ~0.25–0.77 indicate working-capital and timing volatility. This inconsistency raises the risk that earnings quality may not fully convert to cash, constraining reliable reinvestment or buffering against cyclical stress over time.
Variable Returns On CapitalROE variability from mid-single digits to mid-teens implies uneven capital efficiency. Even with low leverage, inconsistent returns suggest the company may face structural challenges in translating investments into superior profit, limiting long-term shareholder value creation versus best-in-class peers.
Sun Pharmaceutical Industries Limited News
SUNPHARMA FAQ
What was Sun Pharmaceutical Industries Limited’s price range in the past 12 months?
Sun Pharmaceutical Industries Limited lowest stock price was ₹1547.25 and its highest was ₹1917.15 in the past 12 months.
What is Sun Pharmaceutical Industries Limited’s market cap?
Sun Pharmaceutical Industries Limited’s market cap is ₹4.29T.
When is Sun Pharmaceutical Industries Limited’s upcoming earnings report date?
Sun Pharmaceutical Industries Limited’s upcoming earnings report date is Jul 30, 2026 which is in 49 days.
How were Sun Pharmaceutical Industries Limited’s earnings last quarter?
Sun Pharmaceutical Industries Limited released its earnings results on May 22, 2026. The company reported ₹11.3 earnings per share for the quarter, missing the consensus estimate of ₹11.341 by -₹0.041.
Is Sun Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Sun Pharmaceutical Industries Limited’s price is currently Overvalued.
Does Sun Pharmaceutical Industries Limited pay dividends?
Sun Pharmaceutical Industries Limited pays a Semiannually dividend of ₹11 which represents an annual dividend yield of 0.91%. See more information on Sun Pharmaceutical Industries Limited dividends here
What is Sun Pharmaceutical Industries Limited’s EPS estimate?
Sun Pharmaceutical Industries Limited’s EPS estimate is 11.59.
How many shares outstanding does Sun Pharmaceutical Industries Limited have?
Sun Pharmaceutical Industries Limited has 2,399,278,300 shares outstanding.
What happened to Sun Pharmaceutical Industries Limited’s price movement after its last earnings report?
Sun Pharmaceutical Industries Limited reported an EPS of ₹11.3 in its last earnings report, missing expectations of ₹11.341. Following the earnings report the stock price went down -2.43%.
Which hedge fund is a major shareholder of Sun Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IN:SUNPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―